Florence Van Obbergh

Author

Hôpital de Jolimont

Also Known As

F. Van Obbergh, F. van Obbergh, Florence Obbergh, Florence Van Obbergh

Publications

213

Citations

H-Index

Concepts

All Affiliations

Hôpital de Jolimont CHU Dinant Godinne UCL Namur Hovon AZ Delta Amsterdam University Medical Centers

About

Florence Van Obbergh is an author at Hôpital de Jolimont specializing in hematology, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	100
2	Immunology	2	2	80
3	Pathology	2	2	80
4	Health Sciences	1	1	17
5	Public Health	1	1	63

Florence Van Obbergh

Publications

160

Citations

H-Index

Page 1

	Year	Citations
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations Carla Al Assaf, Florence Van Obbergh, Johan Billiet, Haematologica Essential ThrombocythemiaGeneticsGenetic EpidemiologyImmunologyPathology	2015	63
Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2 Nicolas Boissel, Françoise Huguet, Carlos Graux, Blood	2021	23
Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study Nicolas Boissel, Françoise Huguet, Thibaut Leguay, Blood	2022	23
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome Jeroen J. W. M. Janssen, Bob Löwenberg, Markus G. Manz, Leukemia Hematological MalignancyOncologyElderly PatientsMedicineAcute Myeloid Leukemia	2022	20
The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study Florence Van Obbergh, Laurent Knoops, Timothy Devos, Clinical Biochemistry Hematological MalignancyChronic Myeloid LeukemiaImatinib PlasmaMedicineBelgian Study	2016	17
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS Jeroen J. W. M. Janssen, Bob Löwenberg, Markus G. Manz, Cancers	2021	14

Page 1